Real-world data from HIV patients in the United States show strong efficacy and tolerability of dolutegravir-based two-drug regimens, supporting findings from clinical trials and European real-world data.
In TANDEM, a retrospective multicenter chart review of adults with HIV-1, the investigators analyzed the virologic outcomes and discontinuation among patients initiating or switching to single-tablet dolutegravir-lamivudine (DTG/3TC; Dovato, ViiV Healthcare) or